Delivery Order SPE2DB22D3501-SPE2DB25FXF22
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract valued at $1,710.69. The order was competitively awarded with no set-aside designation and carries an ultimate completion date of August 21, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform fulfillment from its Corporate Office location at that same address. This delivery order is issued...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor, on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100 count). This competitively awarded, non-set-aside contract carries a ceiling value of $1,161.44 with firm fixed pricing and a completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract value of $2,971.21. This competitively awarded, firm fixed-price delivery order is set to be completed by September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 60 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,367.16. The award, issued on August 7, 2025, with an ultimate completion date of August 8, 2025, represents a competitive procurement with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) at a ceiling value of $1,665.22. This firm fixed-price delivery order, with an ultimate completion date of August 19, 2025, represents a competitive award with no set-aside designation. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $2,354.62. This is a non-set-aside competitive award with an ultimate completion date of August 25, 2025, and performance will be executed from the awardee's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.99 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count units) on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award issued under a larger indefinite delivery contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, for the supply of Vyvanse 20 mg capsules (100-count units) valued at $1,318.31. This non-competitive delivery order, issued on August 18, 2025, with an ultimate completion date of August 19, 2025, represents a firm fixed-price contract. The award is executed under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count units) valued at $2,589.86 under a firm fixed-price arrangement. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a non-set-aside competitive award, and AmerisourceBergen will perform the work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Vyvanse 30 mg capsules (100-count units) with a contract ceiling value of $3,071.84. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB25FXF22Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) valued at $1,017.86 with a firm fixed price structure. The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025, and no set-aside designation was applied, indicating the contract was competitively awarded. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 pharmaceutical prime vendor agreement running through December 2026 that supports military healthcare systems globally. As a major pharmaceutical distributor serving federal medical procurement needs, AmerisourceBergen Drug Corp supplies a comprehensive portfolio of medications and medical supplies to the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. The company's federal contract activity demonstrates its established capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains through a flexible contracting framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.0k | 9/8/25 |